cardiotoxicity in patients with breast cancer receiving Anthracycline. Malignant Neoplasms
Conditions
Interventions
Intervention 1: Intervention group: The recipient of the diet protects the heart. First, a history is taken of the patients who have entered the study and completed the consent form. All patients are
Sponsors
School of Traditional Medicine, Traditional Medicine and Materia Medica Research Center,Shahid Behes
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Women age 18-65 Breast cancer (based on pathology response) Candidate for chemotherapy including anthracyclines +/- trastuzumab 25 =BMI = 19 Willingness to participate in the study
Exclusion criteria
Exclusion criteria: History of heart failure History of coronary artery disease Symptoms of heart failure (functional shortness of breath, orthopedics, PND) Ejection Fraction less than or equal to 40 Use of beta-blockers or ACEI Change the chemotherapy regimen for any reason Unwillingness to continue the study Follow less than 70% of trained dietary recommendations History of liver disease (except grade 1 and 2 fatty liver) History of kidney disease (other than history of urinary stones) • History of depression (taking antidepressants) BMI greater than 25 and less than 19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction. Timepoint: In weeks 0, 8 and 18 from the beginning of the intervention. Method of measurement: Echocardiography.;LV global longitudinal Strain (GLS). Timepoint: In weeks 0, 8 and 18 from the beginning of the intervention. Method of measurement: Echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Alteration of the cardiac marker troponin. Timepoint: Weeks 0, 8 and 18 from the beginning of the intervention. Method of measurement: blood test (Measurement of cardiac troponin enzyme). This enzyme is measured by the enzyme immunoassay method according to standard conditions with ELISA device and with a series of calibrated pipettes.;Quality of Life. Timepoint: Weeks 0, 8 and 18 from the beginning of the intervention. Method of measurement: Quality of Life Questionnaire (EORTC - QOL Br23). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGhazaleh Heydarirad
Shahid Beheshti University of Medical Sciences
Outcome results
None listed